Abstract
Background: Diarrhea is a severe side effect of irinotecan, a pro-drug of SN-38 used for the treatment of many types of cancers. Pre-clinical and clinical studies showed that decreasing the colonic exposure of SN-38 can mitigate irinotecan-induced diarrhea.
Objective: The purpose of this study is to evaluate the anti-diarrhea potential of Xiao-Chai-Hu-Tang (XCHT), a traditional Chinese herbal formula, against irinotecan-induced diarrhea by determining if and how XCHT alters the disposition of SN-38.
Methods: LC-MS/MS was used to quantify the concentrations of irinotecan and its major metabolites (i.e., SN-38, SN-38G). An Intestinal perfusion model was used to determine the effect of XCHT on the biliary and intestinal secretions of irinotecan, SN-38, and SN-38G. Pharmacokinetic (PK) studies were performed to determine the impact of XCHT on the blood and fecal concentrations of irinotecan, SN-38, and SN-38G.
Results: The results showed that XCHT significantly inhibits both biliary and intestinal excretions of irinotecan, SN-38, and SN-38G (range: 35% to 95%). PK studies revealed that the fecal concentrations of irinotecan and SN-38 were significantly decreased from 818.35 ± 120.2 to 411.74 ± 138.83 µg/g or from 423.95 ± 76.44 to 245.63 ± 56.72 µg/g (p<0.05) by XCHT, respectively, suggesting the colonic exposure of SN-38 is significantly decreased by XCHT. PK studies also showed that the plasma concentrations of irinotecan, SN-38, and SN-38G were not affected by XCHT.
Conclusion: In conclusion, XCHT significantly decreased the exposure of SN-38 in the gut without affecting its plasma level, thereby possessing the potential of alleviating irinotecan-induced diarrhea without negatively impacting its therapeutic efficacy.
Keywords: Xiao-Chai-Hu-Tang, alleviating, Irinotecan, SN-38, disposition, diarrhea.
Graphical Abstract
[1]
Vincent, R.M.; Lopez-Meyer, M.; McKnight, T.D.; Nessler, C.L. Sustained harvest of camptothecin from the leaves of Camptotheca acuminata. J. Nat. Prod., 1997, 60, 618-619.
[2]
Farhat, F.S. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med. Oncol., 2007, 24, 137-146.
[3]
Pizzolato, J.F.; Saltz, L.B. Irinotecan (Campto) in the treatment of pancreatic cancer. Expert Rev. Anticancer Ther., 2003, 3, 587-593.
[4]
Gershenson, D.M. Irinotecan in epithelial ovarian cancer. Oncology,
(Williston Park) 2002, 16, 29-31.
[5]
Verschraegen, C.F. Irinotecan for the treatment of cervical cancer. Oncology (Williston Park), 2002, 16, 32-34.
[6]
Reese, D.M.; Tchekmedyian, S.; Chapman, Y.; Prager, D.; Rosen, P.J. A phase II trial of irinotecan in hormone-refractory prostate cancer. Invest. New Drugs, 1998, 16, 353-359.
[7]
Mathijssen, R.H.; Loos, W.J.; Verweij, J.; Sparreboom, A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets, 2002, 2, 103-123.
[8]
Yumuk, P.F.; Aydin, S.Z.; Dane, F.; Gumus, M.; Ekenel, M.; Aliustaoglu, M.; Karamanoglu, A.; Sengoz, M.; Turhal, S.N. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Int. J. Colorectal Dis., 2004, 19, 609-610.
[9]
Cheng, C.; Lau, J.E.; Earl, M.A. Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome. J. Community Support. Oncol., 2015, 13, 3-7.
[10]
Richardson, G.; Dobish, R. Chemotherapy induced diarrhea. J. Oncol. Pharm. Pract., 2007, 13, 181-198.
[11]
Smith, N.F.; Figg, W.D.; Sparreboom, A. Pharmacogenetics of irinotecan metabolism and transport: An update. Toxicol. In Vitro, 2006, 20, 163-175.
[12]
Lam, W.; Bussom, S.; Guan, F.; Jiang, Z.; Zhang, W.; Gullen, E.A.; Liu, S.H.; Cheng, Y.C. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci. Transl. Med., 2010, 2, 45ra59.
[13]
Conti, J.A.; Kemeny, N.E.; Saltz, L.B.; Huang, Y.; Tong, W.P.; Chou, T.C.; Sun, M.; Pulliam, S.; Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 1996, 14, 709-715.
[14]
Hecht, J.R. Gastrointestinal toxicity or irinotecan. Oncology (Williston Park), 1998, 12, 72-78.
[15]
Andreyev, J.; Ross, P.; Donnellan, C.; Lennan, E.; Leonard, P.; Waters, L. Wedlake, J. Bridgewater, R. Glynne-Jones, W. Allum, I. Chau, C.; Wilson, R.; Ferry, D. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol., 2014, 15, e447-e460.
[16]
Stein, A.; Voigt, W.; Jordan, K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol., 2010, 2, 51-63.
[17]
Lenfers, B.H.; Loeffler, T.M.; Droege, C.M.; Hausamen, T.U. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann. Oncol., 1999, 10, 1251-1253.
[18]
Hoff, P.M.; Saragiotto, D.F.; Barrios, C.H.; del Giglio, A.; Coutinho, A.K.; Andrade, A.C.; Dutra, C.; Forones, N.M.; Correa, M.; Portella Mdo, S.; Passos, V.Q.; Chinen, R.N.; van Eyll, B. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J. Clin. Oncol., 2014, 32, 1006-1011.
[19]
Lima-Junior, R.C.; Figueiredo, A.A.; Freitas, H.C.; Melo, M.L.; Wong, D.V.; Leite, C.A.; Medeiros, R.P.; Marques-Neto, R.D.; Vale, M.L.; Brito, G.A.; Oria, R.B.; Souza, M.H.; Cunha, F.Q.; Ribeiro, R.A. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother. Pharmacol., 2012, 69, 931-942.
[20]
Ribeiro, R.A.; Wanderley, C.W.; Wong, D.V.; Mota, J.M.; Leite, C.A.; Souza, M.H.; Cunha, F.Q.; Lima-Junior, R.C. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemother. Pharmacol., 2016, 78, 881-893.
[21]
Wallace, B.D.; Wang, H.; Lane, K.T.; Scott, J.E.; Orans, J.; Koo, J.S.; Venkatesh, M.; Jobin, C.; Yeh, L.A.; Mani, S.; Redinbo, M.R. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 2010, 330, 831-835.
[22]
Kurita, A.; Kado, S.; Matsumoto, T.; Asakawa, N.; Kaneda, N.; Kato, I.; Uchida, K.; Onoue, M.; Yokokura, T. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of beta-glucuronidase activity in intestinal lumen. Cancer Chemother. Pharmacol., 2011, 67, 201-213.
[23]
Yokooji, T.; Kawabe, Y.; Mori, N.; Murakami, T. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats. J. Pharm. Pharmacol., 2013, 65, 280-291.
[24]
Valenti Moreno, V.; Brunet Vidal, J.; Manzano Alemany, H.; Salud Salvia, A.; Llobera Serentill, M.; Cabezas Montero, I.; Servitja, S.; Tormo, E.; Bert, S.; Guma Padro, J. Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clin. Transl. Oncol., 2006, 8, 208-212.
[25]
Gupta, E.; Wang, X.; Ramirez, J.; Ratain, M.J. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother. Pharmacol., 1997, 39, 440-444.
[26]
Desai, A.A.; Kindler, H.L.; Taber, D.; Agamah, E.; Mani, S.; Wade-Oliver, K.; Ratain, M.J.; Vokes, E.E. Modulation of irinotecan with cyclosporine: A phase II trial in advanced colorectal cancer. Cancer Chemother. Pharmacol., 2005, 56, 421-426.
[27]
Horikawa, M.; Kato, Y.; Sugiyama, Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res., 2002, 19, 1345-1353.
[28]
Chester, J.D.; Joel, S.P.; Cheeseman, S.L.; Hall, G.D.; Braun, M.S.; Perry, J.; Davis, T.; Button, C.J.; Seymour, M.T. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. J. Clin. Oncol., 2003, 21, 1125-1132.
[29]
Vasudev, N.S.; Jagdev, S.; Anthoney, D.A.; Seymour, M.T. Intravenous
irinotecan plus oral ciclosporin. Clin. Oncol., (R Coll Radiol), 2005, 17, 646-649.
[30]
Mori, K.; Kondo, T.; Kamiyama, Y.; Kano, Y.; Tominaga, K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol., 2003, 51, 403-406.
[31]
Kummar, S.; Copur, M.S.; Rose, M.; Wadler, S.; Stephenson, J.; O’Rourke, M.; Brenckman, W.; Tilton, R.; Liu, S.H.; Jiang, Z.; Su, T.; Cheng, Y.C.; Chu, E. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer, 2011, 10, 85-96.
[32]
Deng, C.; Deng, B.; Jia, L.; Tan, H.; Zhang, P.; Liu, S.; Zhang, Y.; Song, A.; Pan, L. Preventive effects of a chinese herbal formula, shengjiang xiexin decoction, on irinotecan-induced delayed-onset diarrhea in rats. Evid. Based Complement. Alternat. Med., 2017, 2017, 7350251.
[33]
Fujiwara, K.; Mochida, S.; Nagoshi, S.; Iijima, O.; Matsuzaki, Y.; Takeda, S.; Aburada, M. Regulation of hepatic macrophage function by oral administration of xiao-chai-hu-tang (sho-saiko-to, TJ-9) in rats. J. Ethnopharmacol., 1995, 46, 107-114.
[34]
Zheng, N.; Dai, J.; Cao, H.; Sun, S.; Fang, J.; Li, Q.; Su, S.; Zhang, Y.; Qiu, M.; Huang, S. Current understanding on antihepatocarcinoma effects of xiao chai hu tang and its constituents. Evid. Based Complement. Alternat. Med., 2013, 2013, 529458.
[35]
Qin, X.K.; Li, P.; Han, M.; Liu, J.P. Xiaochaihu Tang for treatment of chronic hepatitis B: A systematic review of randomized trials. Zhong Xi Yi Jie He Xue Bao, 2010, 8, 312-320.
[36]
Ohtake, N.; Nakai, Y.; Yamamoto, M.; Sakakibara, I.; Takeda, S.; Amagaya, S.; Aburada, M. Separation and isolation methods for analysis of the active principles of Sho-saiko-to (SST) oriental medicine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 812, 135-148.
[37]
Hernandez-Boussard, T.; Whirl-Carrillo, M.; Hebert, J.M.; Gong, L.; Owen, R.; Gong, M.; Gor, W.; Liu, F.; Truong, C.; Whaley, R.; Woon, M.; Zhou, T.; Altman, R.B.; Klein, T.E. The pharmacogenetics and pharmacogenomics knowledge base: Accentuating the knowledge. Nucleic Acids Res., 2008, 36, D913-D918.
[38]
Innocenti, F.; Undevia, S.D.; Ramirez, J.; Mani, S.; Schilsky, R.L.; Vogelzang, N.J.; Prado, M.; Ratain, M.J. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin. Pharmacol. Ther., 2004, 76, 490-502.
[39]
Kaur, M.; Badhan, R.K. Phytoestrogens modulate breast cancer resistance protein expression and function at the blood-cerebrospinal fluid barrier. J. Pharm. Pharm. Sci., 2015, 18, 132-154.
[40]
Stappaerts, J.; Brouwers, J.; Annaert, P.; Augustijns, P. In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities. Int. J. Pharm., 2015, 478, 665-681.
[41]
Gao, Y.; Shao, J.; Jiang, Z.; Chen, J.; Gu, S.; Yu, S.; Zheng, K.; Jia, L. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discov. Today, 2014, 19, 326-340.
[42]
Sun, R.; Zeng, M.; Du, T.; Li, L.; Yang, G.; Hu, M.; Gao, S. Simultaneous determinations of 17 marker compounds in Xiao-Chai-Hu-Tang by LC-MS/MS: Application to its pharmacokinetic studies in mice. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2015, 1003, 12-21.
[43]
Basu, S.; Zeng, M.; Yin, T.; Gao, S.; Hu, M. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2016, 1015-1016, 34-41.
[44]
Xia, B.; Zhou, Q.; Zheng, Z.; Ye, L.; Hu, M.; Liu, Z. A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut. Mol. Pharm., 2012, 9, 3246-3258.
[45]
Kulkarni, K.H.; Yang, Z.; Niu, T.; Hu, M. Effects of estrogen and estrus cycle on pharmacokinetics, absorption, and disposition of genistein in female Sprague-Dawley rats. J. Agric. Food Chem., 2012, 60, 7949-7956.
[46]
Chen, J.; Lin, H.; Hu, M. Metabolism of flavonoids via enteric recycling: Role of intestinal disposition. J. Pharmacol. Exp. Ther., 2003, 304, 1228-1235.
[47]
Yeh, Y.S.; Tsai, H.L.; Huang, C.W.; Wang, J.H.; Lin, Y.W.; Tang, H.C.; Sung, Y.C.; Wu, C.C.; Lu, C.Y.; Wang, J.Y. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials, 2016, 17, 46.
[48]
Mathijssen, R.H.; Verweij, J.; Loos, W.J.; de Bruijn, P.; Nooter, K.; Sparreboom, A. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. Br. J. Cancer, 2002, 87, 144-150.
[49]
Canal, P.; Gay, C.; Dezeuze, A.; Douillard, J.Y.; Bugat, R.; Brunet, R.; Adenis, A.; Herait, P.; Lokiec, F.; Mathieu-Boue, A. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol., 1996, 14, 2688-2695.
[50]
Daniella Lowenberg, C.F.T. Michelle Whirl-Carrillo., https://www. pharmgkb.org/pathway/PA20012017.
[51]
Takemoto, I.; Itagaki, S.; Chiba, M.; Itoh, T.; Hirano, T.; Iseki, K. Characterization of secretory intestinal transport of the lactone form of CPT-11. Cancer Chemother. Pharmacol., 2006, 57, 129-133.
[52]
Arimori, K.; Kuroki, N.; Kumamoto, A.; Tanoue, N.; Nakano, M.; Kumazawa, E.; Tohgo, A.; Kikuchi, M. Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents. Pharm. Res., 2001, 18, 814-822.
[53]
Enomoto, R.; Koshiba, C.; Suzuki, C.; Lee, E. Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother. Pharmacol., 2011, 67, 1063-1072.
[54]
Abdallah, H.M.; Al-Abd, A.M.; El-Dine, R.S.; El-Halawany, A.M. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. J. Adv. Res., 2015, 6, 45-62.
[55]
Yu, C.P.; Hsieh, Y.C.; Shia, C.S.; Hsu, P.W.; Chen, J.Y.; Hou, Y.C.; Hsieh, Y.W. Increased systemic exposure of methotrexate by a polyphenol-rich herb via modulation on efflux transporters multidrug resistance-associated protein 2 and breast cancer resistance protein. J. Pharm. Sci., 2016, 105, 343-349.
[56]
Itoh, T.; Itagaki, S.; Sumi, Y.; Hirano, T.; Takemoto, I.; Iseki, K. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2. Cancer Chemother. Pharmacol., 2005, 55, 420-424.
[57]
Ueno, Y.; Matsuda, H.; Mizutani, H.; Iwamoto, T.; Okuda, M. Involvement of specific transport system on uptake of lactone form of SN-38 in human intestinal epithelial cell line Caco-2. Biol. Pharm. Bull., 2012, 35, 54-58.
[58]
Kitagawa, S.; Takahashi, T.; Nabekura, T.; Tachikawa, E.; Hasegawa, H. Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells. Biol. Pharm. Bull., 2007, 30, 1979-1981.
[59]
Yu, C.P.; Wu, P.P.; Hou, Y.C.; Lin, S.P.; Tsai, S.Y.; Chen, C.T.; Chao, P.D. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J. Agric. Food Chem., 2011, 59, 4644-4648.
[60]
Hyatt, J.L.; Tsurkan, L.; Wierdl, M.; Edwards, C.C.; Danks, M.K.; Potter, P.M. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity. Mol. Cancer Ther., 2006, 5, 2281-2288.
[61]
Prados, M.D.; Yung, W.K.; Jaeckle, K.A.; Robins, H.I.; Mehta, M.P.; Fine, H.A.; Wen, P.Y.; Cloughesy, T.F.; Chang, S.M.; Nicholas, M.K.; Schiff, D.; Greenberg, H.S.; Junck, L.; Fink, K.L.; Hess, K.R.; Kuhn, J. North American brain tumor consortium, phase 1 trial of irinotecan (cpt-11) in patients with recurrent malignant glioma: A North American brain tumor consortium study. Neuro-oncol., 2004, 6, 44-54.
[62]
Takasuna, K.; Kasai, Y.; Kitano, Y.; Mori, K.; Kobayashi, R.; Hagiwara, T.; Kakihata, K.; Hirohashi, M.; Nomura, M.; Nagai, E.; Kamataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 1995, 86, 978-984.
[63]
Flieger, D.; Klassert, C.; Hainke, S.; Keller, R.; Kleinschmidt, R.; Fischbach, W. Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology, 2007, 72, 10-16.
[64]
Mego, M.; Chovanec, J.; Vochyanova-Andrezalova, I.; Konkolovsky, P.; Mikulova, M.; Reckova, M.; Miskovska, V.; Bystricky, B.; Beniak, J.; Medvecova, L.; Lagin, A.; Svetlovska, D.; Spanik, S.; Zajac, V.; Mardiak, J.; Drgona, L. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement. Ther. Med., 2015, 23, 356-362.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Metabolism
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
Article Metrics
55
5
1
3